Pancreatic Cancer Clinical Trial Drug Development Pipeline Expands With Contributions From 170+ Key Companies Delveinsight

(MENAFN- GetNews) The Pancreatic Cancer Clinical Trial analysis report delivers important insights into ongoing research of 170+ pipeline Pancreatic Cancer Drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

(Albany, US) September 16, 2026 - DelveInsight's “Pancreatic Cancer Pipeline Insight 2026” report provides comprehensive insights about 170+ companies and 200+ pipeline drugs in the Pancreatic Cancer pipeline landscape. It covers the Pancreatic Cancer pipeline drug profiles, including clinical and nonclinical-stage products. It also covers the Pancreatic Cancer Pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download DelveInsight's comprehensive Pancreatic Cancer Pipeline Report @

Key Takeaways from the Pancreatic Cancer Pipeline Report

• On September 16, 2026, Evopoint Biosciences Inc. conducted a study was a randomized, double-blind, multicenter phase III clinical study. A total of 226 patients with metastatic pancreatic ductal carcinoma who had failed or were intolerant to two previous standard therapies were planned will be randomized in a 2:1 ratio to either the experimental group or the control group:Experimental Group: XNW28012 for Injection (2.4 mg/kg, administered once every 3 weeks);Control group: XNW28012 mimetic for Injection (administered once every 3 weeks).Both experimental and control subjects will receive optimal supportive care, including but not limited to nutritional support, adjustment of electrolyte balance, and cancer pain support treatment.
• On September 10, 2026, Exelixis initiated a phase 2/3 study to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
• DelveInsight's Pancreatic Cancer pipeline report depicts a robust space with 170+ active players working to develop 200+ pipeline therapies for Pancreatic Cancer treatment.
• The leading Pancreatic Cancer Companies such as Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., Oncotelic Inc., Golden Biotechnology Corp., Cantargia AB, Marker Therapeutics, Inc., NanoPharmaceuticals, Innovent Biologics/Takeda, Verastem, Inc., Autotelic Bio Inc., Oncolytics Biotech, Agenus Inc., ONO PHARMACEUTICAL CO., LTD., Merck Sharp & Dohme LLC., Akeso Biopharma Co., Ltd., ImmunityBio, Inc., NETRIS Pharma, Merck & Co., Inc., Nihon Medi-Physics Co., Ltd., FutureGen Biopharmaceutical (Beijing) Co., Ltd., Can-Fite Biopharma, and InxMed and others
• Promising Pancreatic Cancer Pipeline Therapies such as Gemcitabine plus TS-1, Gemcitabine, FOLFOX, Nanoplatin (NC-6004), and Gemcitabine, and others.

Stay ahead with the most recent pipeline outlook for Pancreatic Cancer @ Pancreatic Cancer Treatment Drugs

Pancreatic cancer Overview

Pancreatic cancer is a malignant neoplasm that arises primarily from the ductal epithelial cells of the pancreas, most commonly presenting as pancreatic ductal adenocarcinoma. It is considered one of the most aggressive and lethal cancers, ranking among the leading causes of cancer-related mortality worldwide. The disease is characterized by poor prognosis, with reported 5-year survival rates generally ranging between 5% and 15%, reflecting its highly aggressive nature and late detection. Histologically, the majority of cases are adenocarcinomas, with tumors most frequently originating in the head of the pancreas, although they can also arise in the body and tail.

Pancreatic cancer Emerging Drugs

• TQB2868: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

TQB2868 injection is a PD-1/TGF-β bifunctional fusion protein independently developed by Chia Tai Tianqing Pharmaceutical Group. It can block the PD-1/PD-L1 pathway and neutralize TGF-β in the tumor microenvironment, exhibiting dual effects of immune checkpoint inhibition and tumor microenvironment remodeling. The combined inhibition of PD-1 and TGF-β signaling can lead to a more effective anti-tumor immune response than inhibition of either pathway alone, thereby improving clinical benefits in anti-tumor treatment. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of pancreatic cancer.

• Trabedersen (OT-101): Oncotelic Inc./ Autotelic Bio Inc.

Trabedersen, also referred as OT-101 is a novel antisense oligodeoxynucleotide (ODN). It is a synthetic 18-mer phosphorothioate oligodeoxynucleotide (S-ODN) complementary to the messenger ribonucleic acid (mRNA) of the human TGF-β2 gene. Cancers overexpress TGF-β, which suppresses host innate immune response to the cancers. Treatment with OT-101 lifts the TGF-β cloaking effect and allows innate or therapeutic immunity to attack and eliminate the cancers. The drug has showed favorable safety and long-term disease control in over half of the treated patients in PDAC. Currently, the drug is being evaluated in the Phase II/III stage of its development for the treatment of pancreatic cancer.

• Antroquinonol: Golden Biotechnology Corp.

Antroquinonol is a small molecule NCE with demonstrated activities both in-vivo and in-vitro against a number of malignancies, infectious diseases and neuro-degenerative diseases. Antroquinonol inhibited Ras and Ras-related GTP-binding protein activation through inhibition of protein isoprenyl transferase activity, leading to activation of autophagy and associated mode of cell death in cancer cells. Additionally, it can be taken orally, providing a convenient treatment option for patients. Antroquinonol has gained recognition for its groundbreaking work in the field of cancer treatment. It has been granted Orphan Drug Designation (ODD) by the FDA for the treatment of Pancreatic Cancer. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of pancreatic cancer.

• Nadunolimab: Cantargia AB

Nadunolimab (CAN04) is an Anti-IL1RAP antibody for treatment of various cancer types. Nadunolimab binds strongly to its target molecule IL1RAP, expressed on tumor cells from many types of cancer. Nadunolimab blocks the signaling of interleukin-1, alpha and beta, thereby limiting tumor development as well as working synergistically with chemotherapy and adding functionality through Antibody-Dependent Cellular Cytotoxicity (ADCC). In June 2025, the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to nadunolimab for for the treatment of patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC) with high expression levels of IL1RAP in combination with gemcitabine and nab-paclitaxel. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of pancreatic cancer.

• MT-601: Marker Therapeutics, Inc.

MT-601 is a promising Multi-Tumor Associated Antigen (multiTAA)-specific T cell therapy developed by Marker Therapeutics for treating advanced or metastatic pancreatic cancer. It is a non-genetically modified therapy that targets six antigens ommonly expressed in pancreatic tumors. Unlike CAR-T therapy, MT-601 is a non-genetically modified T cell product. It targets multiple tumor-associated antigens, which may reduce the risk of immune evasion by the tumor. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of pancreatic cancer.

• fb-PMT: NanoPharmaceuticals

Fb-PMT (NP751) is a novel, potent thyrointegrin antagonist that has shown high effectiveness in preclinical studies for pancreatic cancer, reducing tumor weight and viability by over 90% in mice Fb-PMT works by targeting the thyrointegrin receptor, which is overexpressed on the surface of pancreatic cancer cells and dividing blood vessel cells, inducing anti-angiogenic and anticancer effects. Currently, the drug is being evaluated in the preclinical stage of its development for the treatment of pancreatic cancer.

Explore groundbreaking therapies and clinical trials in the Pancreatic Cancer Pipeline @ New Pancreatic Cancer Drugs

The Pancreatic Cancer Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Pancreatic Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pancreatic Cancer treatment.
• Pancreatic Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Pancreatic Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pancreatic Cancer market.

Pancreatic Cancer Companies

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., Oncotelic Inc., Golden Biotechnology Corp., Cantargia AB, Marker Therapeutics, Inc., NanoPharmaceuticals, Innovent Biologics/Takeda, Verastem, Inc., Autotelic Bio Inc., Oncolytics Biotech, Agenus Inc., ONO PHARMACEUTICAL CO., LTD., Merck Sharp & Dohme LLC., Akeso Biopharma Co., Ltd., ImmunityBio, Inc., NETRIS Pharma, Merck & Co., Inc., Nihon Medi-Physics Co., Ltd., FutureGen Biopharmaceutical (Beijing) Co., Ltd., Can-Fite Biopharma, and InxMed and others.

Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Pancreatic Cancer Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Learn about new drugs, pipeline developments, and key companies with DelveInsight's @ Pancreatic Cancer Market Drivers and Barriers

Scope of the Pancreatic Cancer Pipeline Report

• Coverage- Global
• Pancreatic Cancer Companies- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., Oncotelic Inc., Golden Biotechnology Corp., Cantargia AB, Marker Therapeutics, Inc., NanoPharmaceuticals, Innovent Biologics/Takeda, Verastem, Inc., Autotelic Bio Inc., Oncolytics Biotech, Agenus Inc., ONO PHARMACEUTICAL CO., LTD., Merck Sharp & Dohme LLC., Akeso Biopharma Co., Ltd., ImmunityBio, Inc., NETRIS Pharma, Merck & Co., Inc., Nihon Medi-Physics Co., Ltd., FutureGen Biopharmaceutical (Beijing) Co., Ltd., Can-Fite Biopharma, and InxMed and others
• Pancreatic Cancer Pipeline Therapies- Gemcitabine plus TS-1, Gemcitabine, FOLFOX, Nanoplatin (NC-6004) and Gemcitabine, and others.
• Pancreatic Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Pancreatic Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Pancreatic Cancer drug development? @ Pancreatic Cancer Emerging Drugs and Major Companies

Table of Contents

Introduction

Executive Summary

Pancreatic Cancer: Overview

Pipeline Therapeutics

Therapeutic Assessment

Pancreatic Cancer – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Pamrevlumab: FibroGen

Drug profiles in the detailed report.....

Mid-Stage Products (Phase II)

CT041: CARsgen Therapeutics

Drug profiles in the detailed report.....

Early Stage Products (Phase I/II)

DK210: DEKA Biosciences

Drug profiles in the detailed report.....

Preclinical and Discovery Stage Products

Drug: Company Name

Drug profiles in the detailed report.....

Inactive Products

Pancreatic Cancer Key Companies

Pancreatic Cancer Key Products

Pancreatic Cancer- Unmet Needs

Pancreatic Cancer- Market Drivers and Barriers

Pancreatic Cancer- Future Perspectives and Conclusion

Pancreatic Cancer Analyst Views

Pancreatic Cancer Key Companies

Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

MENAFN17092026003238003268ID1111677181